Moderna has increased in popularity over the last year due to its vaccine.
The images are from radek Mica.
Moderna said its booster shot increases protection against the Omicron variant.
A third dose of Moderna's COVID-19 vaccine increased protection against the variant by 37 times.
Each of the first two vaccine shots uses half of the authorized booster shot's dose level.
Our daily newsletter is called 10 Things Before the Opening Bell.
Moderna stock jumped as much as 9% on Monday after it said that its vaccine booster increases protection against the Omicron variant.
A third dose, which is half the dose level used for each of the first two vaccine shots, resulted in a 37fold increase in antibody protection against the fast-spreading Omicron variant.
The dramatic increase in COVID-19 cases from the Omicron variant is concerning to all. The Chief Executive Officer of Moderna said that the data showing that the Moderna COVID-19 booster can boost neutralizing antibody levels is reassuring.
Moderna noted that the original two-dose vaccine regimen did not provide a strong response to the Omicron variant.
Moderna plans to quickly advance an Omicron-specific booster candidate into its clinical testing in case it becomes necessary in the future to combat the rise of the Omicron variant.
Moderna will continue to develop an Omicron-specific variant vaccine that it expects to advance into clinical trials in early 2022.
Bancel said that they will continue to share data with public health authorities to help them make evidence-based decisions on the best vaccine strategies.
Moderna investors have experienced a 40% decline in the stock since it topped out at $497 in August, and the booster results against Omicron is good news. The stock was up about 1% on Monday. Moderna's shares are up 181% year-to-date.
Markets Insider.
Business Insider has an original article.
